Akèy › Kansè Poumon ki pa ti selil › Illinois › North Peoria
Etid klinik pou Kansè Poumon ki pa ti selil nan North Peoria, IL
11 etid pou Kansè Poumon ki pa ti selil ap chèche patisipan nan sit nan ak bò kote North Peoria (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial
Ap rekriteFaz 3
- Illinois CancerCare - Washington, Washington · 9 mi lwen
- Illinois CancerCare-Eureka, Eureka · 16 mi lwen
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Ap rekriteFaz 3
- Illinois CancerCare - Washington, Washington · 9 mi lwen
A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment
Ap rekriteFaz 2
- Illinois CancerCare - Washington, Washington · 9 mi lwen
- Illinois CancerCare-Eureka, Eureka · 16 mi lwen
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
Ap rekriteFaz 3
- Illinois CancerCare - Washington, Washington · 9 mi lwen
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Ap rekriteFaz 3
- Illinois CancerCare-Washington, Washington · 9 mi lwen
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
Ap rekriteFaz 2
- Illinois CancerCare - Washington, Washington · 9 mi lwen
- Illinois CancerCare-Eureka, Eureka · 16 mi lwen
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
Ap rekriteFaz 2
- Illinois CancerCare - Washington, Washington · 9 mi lwen
- Illinois CancerCare-Eureka, Eureka · 16 mi lwen
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
Ap rekriteFaz 2
- Illinois CancerCare - Washington, Washington · 9 mi lwen
- Illinois CancerCare-Eureka, Eureka · 16 mi lwen
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
Ap rekriteFaz 2/3
- Illinois CancerCare - Washington, Washington · 9 mi lwen
- Illinois CancerCare-Eureka, Eureka · 16 mi lwen
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
Ap rekriteFaz 2
- Illinois CancerCare - Washington, Washington · 9 mi lwen
- Illinois CancerCare-Eureka, Eureka · 16 mi lwen
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
Ap rekriteEtid obsèvasyon
- Illinois CancerCare - Washington, Washington · 9 mi lwen
- Illinois CancerCare-Eureka, Eureka · 16 mi lwen
Etid Kansè Poumon ki pa ti selil nan lòt vil
- Houston, TX145 etid
- New York City, NY121 etid
- Arlington, VA104 etid
- Nashville, TN97 etid
- Boston, MA90 etid
- Los Angeles, CA87 etid
- St. Louis, MO73 etid
- Chicago, IL61 etid
- Baltimore, MD60 etid
- San Antonio, TX59 etid
- Columbus, OH57 etid
- Washington, DC55 etid
Lòt etid nan North Peoria
- Kansè poumon9 etid
- Kansè kolorektal7 etid
- Kansè pwostat6 etid
- Kansè nan tete5 etid
- Karsinòm selil skuamèz tèt ak kou5 etid
- Kansè pankreyas4 etid
- Leksemi mieloïd egi4 etid
- Kansè kolon4 etid
- Melanom4 etid
- Kansè Ipofaringe4 etid
- Kansè larinks4 etid
- Kansè bouch4 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.